Haemonetics Corporation’s (HAE) share price has entered into oversold territory with a stochastic value of 12.81. The Zacks Consensus Estimate on the company’s earnings for year ending March 2011 increased by a cent over the past two months to $3.22 per share. Haemonetics is a Zacks #2 Rank (“Buy”) company.
 
HAEMONETICS CP (HAE): Free Stock Analysis Report
 
Zacks Investment Research